GeneOne Life Science Decides to Acquire 4.1 Billion Won Convertible Bonds Before Maturity... Plans Resale for Operating Funds and Manages Potential Dilution Risk
GeneOne Life Science decided on June 17, 2026 to acquire its 7th series unsecured private convertible bonds worth 4.1 billion won before maturity through an agreement with bondholder DoYoung Mulsan.
The acquisition amount is the principal of 4.1 billion won with no interest or yield paid, meaning the bondholder waived interest income.
The acquisition was funded with internal cash, and the acquired bonds will be resold to a third party to secure operating funds.
The conversion price of the bonds is 1,065 won, 20.3% higher than the current stock price of 885 won, reducing conversion incentive, but potential dilution remains from the remaining 1 billion won bonds and future resale.
The shares to be issued upon full conversion amount to 4,788,732 shares, representing 5.27% of total outstanding shares.
The seller DoYoung Mulsan is a small corporation with assets of 99 million won and sales of 32 million won, posing transparency risks.
[AI Summary]GeneOne Life Science reduced short-term debt by acquiring 4.1 billion won convertible bonds before maturity, but the resale plan introduces medium-term dilution risk and uncertainty in operating fund procurement. The transaction with a small counterparty raises governance concerns, and stock price recovery depends on resale terms and business performance.
KOSPI Filing Information
Report On Major Events (Decision On Acquisition Before Maturity Of Self-Convertible Bonds)